MD Anderson Cancer Center to acquire Elekta linear accelerators and other radiotherapy solutions

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Endo Announces Peyronie’s Disease Presentation at...

Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today...

Leadership at NHS Hospitals in Leeds...

A watchdog has gone on to say that the...

Developing Dr. CaBot, A Medical Education...

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for...

The medicines regulator of the UK has announced plans...
The University of Texas MD Anderson Cancer Center has signed a deal with Elekta (EKTA-B.ST) to acquire Elekta Infinity™ linear accelerators, brachytherapy afterloaders as well as software and service.  
Bill Yaeger, Elekta’s Executive Vice President, Region North America, says: “As a world-renowned cancer center, MD Anderson has been a technology leader in managing the disease. In addition to being one of the first U.S. medical centers to acquire Elekta’s new Leksell Gamma Knife® Icon™ brain radiosurgery system, MD Anderson is also part of the consortium to develop the world’s first high-field MR-guided linear accelerator. We are proud that it has chosen us again in the expansion of its facilities in Texas. Both organizations share a commitment to quality and the best care possible for patients.”  
The order, for four Infinity treatment systems, will also include Elekta’s high-resolution beam shaping solution, the Agility™ 160-leaf multi-leaf collimator.  
The deal also includes four high-dose-rate (HDR) brachytherapy afterloaders and Oncentra® Brachy treatment planning; MOSAIQ® Oncology Information System (OIS); Active Breathing Coordinator™ units; as well as service for the hardware and software.

Latest stories

Related stories

Developing Dr. CaBot, A Medical Education Tool That Reasons

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for Medtech Regulatory Reforms

The medicines regulator of the UK has announced plans...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »